Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Threat Sensitivity in Alcohol Use Disorder
NCT05656534Phase 1Completed
- Sponsor
- The Ohio State University
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suvorexant in alcohol use disorder (AUD) (2 arms), sponsored by The Ohio State University. Primary endpoints: Startle Eyeblink Electromyographic (EMG) Response to Stress With an Acute Dose of Suvorexant, Startle Eyeblink Electromyographic (EMG) Response to Stress With Daily Use of Suvorexant at 4 weeks and 1 more. Started Nov 2022; status: completed.
02
Drugs
suvorexant
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05656534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656534.